| Nomograms in oncology: more than meets the eye VP Balachandran, M Gonen, JJ Smith, RP DeMatteo The lancet oncology 16 (4), e173-e180, 2015 | 2404 | 2015 |
| Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer VP Balachandran, M Łuksza, JN Zhao, V Makarov, JA Moral, R Remark, ... Nature 551 (7681), 512-516, 2017 | 988 | 2017 |
| Extracellular vesicle and particle biomarkers define multiple human cancers A Hoshino, HS Kim, L Bojmar, KE Gyan, M Cioffi, J Hernandez, ... Cell 182 (4), 1044-1061. e18, 2020 | 810 | 2020 |
| Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido VP Balachandran, MJ Cavnar, S Zeng, ZM Bamboat, LM Ocuin, H Obaid, ... Nature medicine 17 (9), 1094-1100, 2011 | 596 | 2011 |
| A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy M Łuksza, N Riaz, V Makarov, VP Balachandran, MD Hellmann, ... Nature 551 (7681), 517-520, 2017 | 593 | 2017 |
| Broadening the impact of immunotherapy to pancreatic cancer: challenges and opportunities VP Balachandran, GL Beatty, SK Dougan Gastroenterology 156 (7), 2056-2072, 2019 | 348 | 2019 |
| Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer LA Rojas, Z Sethna, KC Soares, C Olcese, N Pang, E Patterson, J Lihm, ... Nature 618 (7963), 144-150, 2023 | 276 | 2023 |
| ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity JA Moral, J Leung, LA Rojas, J Ruan, J Zhao, Z Sethna, A Ramnarain, ... Nature 579 (7797), 130-135, 2020 | 269 | 2020 |
| Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors C Valero, M Lee, D Hoen, K Weiss, DW Kelly, PS Adusumilli, PK Paik, ... Nature communications 12 (1), 729, 2021 | 241 | 2021 |
| Toll‐like receptor 9 inhibition confers protection from liver ischemia–reperfusion injury ZM Bamboat, VP Balachandran, LM Ocuin, H Obaid, G Plitas, ... Hepatology 51 (2), 621-632, 2010 | 218 | 2010 |
| Conventional DCs reduce liver ischemia/reperfusion injury in mice via IL-10 secretion ZM Bamboat, LM Ocuin, VP Balachandran, H Obaid, G Plitas, ... The Journal of clinical investigation 120 (2), 559-569, 2010 | 214 | 2010 |
| Actual 10-year survival after hepatic resection of colorectal liver metastases: what factors preclude cure? JM Creasy, E Sadot, BG Koerkamp, JF Chou, M Gonen, NE Kemeny, ... Surgery 163 (6), 1238-1244, 2018 | 195 | 2018 |
| Real-time genomic profiling of pancreatic ductal adenocarcinoma: potential actionability and correlation with clinical phenotype MA Lowery, EJ Jordan, O Basturk, RN Ptashkin, A Zehir, MF Berger, ... Clinical Cancer Research 23 (20), 6094-6100, 2017 | 181 | 2017 |
| Stratification of pancreatic ductal adenocarcinoma: combinatorial genetic, stromal, and immunologic markers ES Knudsen, P Vail, U Balaji, H Ngo, IW Botros, V Makarov, N Riaz, ... Clinical Cancer Research 23 (15), 4429-4440, 2017 | 179 | 2017 |
| Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection W Park, J Chen, JF Chou, AM Varghese, KH Yu, W Wong, M Capanu, ... Clinical Cancer Research 26 (13), 3239-3247, 2020 | 163 | 2020 |
| The association between tumor mutational burden and prognosis is dependent on treatment context C Valero, M Lee, D Hoen, J Wang, Z Nadeem, N Patel, MA Postow, ... Nature genetics 53 (1), 11-15, 2021 | 160 | 2021 |
| Pancreas cancer‐associated weight loss AE Hendifar, MQB Petzel, TA Zimmers, CS Denlinger, LM Matrisian, ... The oncologist 24 (5), 691-701, 2019 | 153 | 2019 |
| Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: a … A Cercek, T Boerner, BR Tan, JF Chou, M Gönen, TM Boucher, ... JAMA oncology 6 (1), 60-67, 2020 | 148 | 2020 |
| Improved prediction of immune checkpoint blockade efficacy across multiple cancer types D Chowell, SK Yoo, C Valero, A Pastore, C Krishna, M Lee, D Hoen, ... Nature biotechnology 40 (4), 499-506, 2022 | 146 | 2022 |
| KIT oncogene inhibition drives intratumoral macrophage M2 polarization MJ Cavnar, S Zeng, TS Kim, EC Sorenson, LM Ocuin, VP Balachandran, ... Journal of Experimental Medicine 210 (13), 2873-2886, 2013 | 142 | 2013 |
